The role of osteoprotegerin and receptor activator of nuclear factor κB ligand in the pathogenesis and treatment of rheumatoid arthritis

Arthritis and Rheumatism

Volumn 44, Issue 2, 2001, Pages 253-259

  Hofbauer, Lorenz C ^a   Heufelder, Armin E ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; CYTOKINE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 11; INTERLEUKIN 17; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN; PROTEIN RANK; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

BONE METABOLISM; DENDRITIC CELL; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION;

ANIMALS; ARTHRITIS, RHEUMATOID; GLYCOPROTEINS; HUMANS; LIGANDS; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0035089788     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200102)44:2<253::AID-ANR41>3.0.CO;2-S     Document Type: Review

References (54)

1. Generalized bone loss in patients with rheumatoid arthritis
2. Pathogenesis of bone erosions in rheumatoid arthritis
3. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint
4. Identification of cell types responsible for bone resorption in rheumatoid arthritis juvenile rheumatoid arthritis
5. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
6. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function
7. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
8. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation
9. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
10. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells
11. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
12. Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival
13. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation
14. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro
15. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
16. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
17. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation function
18. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
19. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
20. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation activation induced by osteoprotegerin ligand
21. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis
22. RANK is essential for osteoclast lymph node development
23. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
24. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
25. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
26. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
27. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin
28. TRANCE (Tumor necrosis factor [TNF]-related activation-induced cytokine). A new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor
29. TRANCE, a TNF family member, is differentially expressed on T cell subsets induces cytokine production in dendritic cells
30. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation
31. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40
32. Role of cytokines in rheumatoid arthritis
33. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6 stimulate osteoprotegerin ligand gene expression in human osteoblastic cells
34. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
35. Activated T cells support osteoclast formation in vitro
36. The inhibitory effect of interleukin-10 on mouse osteoclast formation involves novel tyrosine-phosphorylated proteins
37. Interleukin 4, interferon-γ, prostaglandin E impact the osteoclastic cell-forming potential of routine bone marrow macrophages
38. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis
39. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor
40. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis
41. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
42. Presence of osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluids from patients with rheumatoid arthritis
43. Rheumatoid arthritis synodal macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent
44. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy
45. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy
46. 3
47. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord
48. Osteoprotegerin mitigates tail suspension-induced osteopenia
49. Osteoprotegerin (OPG) has potent and sustained anti-resorptive activity in postmenopausal women
50. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosions
51. Arthritis patterns in rats with adjuvant-induced arthritis define distinct mechanisms of joint protection for IL-1ra, sTNF-RI, and OPG
52. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis
53. Mechanical strain inhibits expression of osteoclast differentiation factor by murine stromal cells
54. Decoy receptors thwart B cells